Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials

@article{Kavirajan2007EfficacyAA,
  title={Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials},
  author={H. Kavirajan and L. Schneider},
  journal={The Lancet Neurology},
  year={2007},
  volume={6},
  pages={782-792}
}
  • H. Kavirajan, L. Schneider
  • Published 2007
  • Medicine
  • The Lancet Neurology
  • BACKGROUND Cholinesterase inhibitors and memantine do not have regulatory approval in most of the world for treatment of vascular dementia. A systematic review and meta-analysis was undertaken to assess the evidence for efficacy and safety of cholinesterase inhibitors and memantine in vascular dementia. METHODS PubMed, BIOSIS, International Pharmaceutical Abstracts, and Cochrane registries were searched for randomised, placebo-controlled trials on cholinesterase inhibitors and memantine in… CONTINUE READING
    Memantine for dementia.
    • 449
    A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence
    • 75
    • Highly Influenced
    Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology
    • 125
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 29 REFERENCES
    Memantine for dementia.
    • 449